ERBB2 and neoplasm: In breast cancer models it has been demonstrated that BCL-3 drives metastasis of tumour cells (55, 56): In HER2-positive breast tumour cells, BCL-3 knockout (KO) resulted in an 80% reduction of metastatic burden in mice following tail-vein injection of tumour cells (55).